MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON AND SURVIVAL EXTRAPOLATION IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-REFRACTORY DTC): UPDATED ANALYSIS

被引：2
|
作者：
Tremblay, G. [1 ]
Pelletier, C. [1 ]
Forsythe, A. [2 ]
Majethia, U. [2 ]
机构：
[1] Eisai, Woodcliff Lake, NJ USA
[2] Eisai Inc, Woodcliff Lake, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1048
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN33
引用
收藏
页码：A435 / A435
页数：1
相关论文
共 50 条
  • [41] Matching-Adjusted Indirect Treatment Comparison of Epcoritamab Versus Zanubrutinib Plus Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
    Cumings, Karen
    Chirikov, Viktor
    Ding, Zhijie
    Goncalves, Felipe Marques
    Heaps, Nicole
    Chawla, Savreet Bains
    Wang, Anthony W.
    Atiya, Mohammad
    Navarro, Fernando Rivas
    Favaro, Elena
    Hoehn, Daniela
    Mutebi, Alex
    BLOOD, 2024, 144 : 7802 - 7803
  • [42] 68Ga-DOTA-FAPI-04 PET/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients
    Yun Chen
    Shan Zheng
    Jiaying Zhang
    Shaobo Yao
    Weibing Miao
    Annals of Nuclear Medicine, 2022, 36 : 610 - 622
  • [43] 68Ga-DOTA-FAPI-04 PET/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients
    Chen, Yun
    Zheng, Shan
    Zhang, Jiaying
    Yao, Shaobo
    Miao, Weibing
    ANNALS OF NUCLEAR MEDICINE, 2022, 36 (07) : 610 - 622
  • [44] Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial
    Brose, Marcia S.
    Robinson, Bruce G.
    Sherman, Steven, I
    Jarzab, Barbara
    Lin, Chia-Chi
    Vaisman, Fernanda
    Hoff, Ana O.
    Hitre, Erika
    Bowles, Daniel W.
    Sen, Suvajit
    Oliver, Jennifer W.
    Banerjee, Kamalika
    Keam, Bhumsuk
    Capdevila, Jaume
    CANCER, 2022, 128 (24) : 4203 - 4212
  • [45] Assessment of the efficacy and safety of lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer in real-life practice in Russia
    Borodavina, E.
    Isaev, P.
    Shurinov, A.
    Krylov, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S1089 - S1090
  • [46] TREATMENT PATTERNS AND HEALTH OUTCOMES AMONG PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN THE UNITED STATES AND WESTERN EUROPE
    Gianoukakis, A. G.
    Flores, N. M.
    Pelletier, C. L.
    DiBonaventura, M.
    Forsythe, A.
    Wolfe, G.
    Rege, J.
    Taylor, M. H.
    VALUE IN HEALTH, 2014, 17 (07) : A614 - A614
  • [47] Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients
    Fukuda, Naoki
    Toda, Kazuhisa
    Wang, Xiaofei
    Ohmoto, Akihiro
    Hayashi, Naomi
    Urasaki, Tetsuya
    Sato, Yasuyoshi
    Nakano, Kenji
    Ono, Makiko
    Tomomatsu, Junichi
    Mitani, Hiroki
    Takahashi, Shunji
    ENDOCRINE JOURNAL, 2021, 68 (06) : 639 - 647
  • [48] Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer
    Tahara, Makoto
    Kiyota, Naomi
    Hoff, Ana O.
    Badiu, Corin
    Owonikoko, Taofeek K.
    Dutcus, Corina E.
    Suzuki, Takuya
    Ren, Min
    Wirth, Lori J.
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 51 - 57
  • [49] MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Telford, C.
    Kabadi, S.
    Abhyankar, S.
    Song, J.
    Signorovitch, J.
    Zhao, J.
    Yao, Z.
    VALUE IN HEALTH, 2019, 22 : S62 - S62
  • [50] Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching-Adjusted Indirect Analysis
    Gao, Fenghua
    Sun, Cong
    Liu, Jing
    Yu, Jingwei
    He, Jin
    Meng, Xiangrui
    Liu, Xia
    Han, Xue
    Li, Lanfang
    Qiu, Lihua
    Qian, Zhengzi
    Zhou, Shiyong
    Xia, Zhen
    Yang, Su
    Zhou, Zisong
    Tian, Alex
    Qin, Yun
    Wang, Xianhuo
    Zhang, Huilai
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (02)
12345